GLP-1 is an incretin hormone that simulates insulin secretion and inhibits glucagon secretion
in a glucose dependent way. Below normal plasma glucose levels the effects of GLP-1 stop and
the risk of hypoglycemia is small. However no results exits on the effects pharmacologically
relevant doses of GLP-1 during long-time fasting. There seems to be a risk of hypoglycemia in
healthy people after a fasting period when a glucose load is administered. The risk of
hypoglycemia when GLP-1 is administered will be evaluated during these two conditions.